Cargando…
Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany
BACKGROUND: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle weakness and muscle atrophy. Nusinersen acts as a splicing modifier and has recently been approved for intrathecal treatment of SMA. OBJECTIVE: Prior to approval, nusinersen was provided to patients with SM...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004898/ https://www.ncbi.nlm.nih.gov/pubmed/29689734 http://dx.doi.org/10.3233/JND-180315 |
_version_ | 1783332604177547264 |
---|---|
author | Pechmann, Astrid Langer, Thorsten Schorling, David Stein, Sabine Vogt, Sibylle Schara, Ulrike Kölbel, Heike Schwartz, Oliver Hahn, Andreas Giese, Kerstin Johannsen, Jessika Denecke, Jonas Weiß, Claudia Theophil, Manuela Kirschner, Janbernd |
author_facet | Pechmann, Astrid Langer, Thorsten Schorling, David Stein, Sabine Vogt, Sibylle Schara, Ulrike Kölbel, Heike Schwartz, Oliver Hahn, Andreas Giese, Kerstin Johannsen, Jessika Denecke, Jonas Weiß, Claudia Theophil, Manuela Kirschner, Janbernd |
author_sort | Pechmann, Astrid |
collection | PubMed |
description | BACKGROUND: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle weakness and muscle atrophy. Nusinersen acts as a splicing modifier and has recently been approved for intrathecal treatment of SMA. OBJECTIVE: Prior to approval, nusinersen was provided to patients with SMA type 1 in Germany within an Expanded Access Program (EAP). In contrast to previous clinical trials, children of different age groups and different stages of the disease were treated with nusinersen. METHODS: We conducted a prospective, longitudinal data collection of patients treated with nusinersen within the EAP in seven neuromuscular centers in Germany. Standardized assessments including CHOP-INTEND and HINE-2 motor milestones were performed at baseline and 60 and 180 days after start of treatment. RESULTS: Data from 61 SMA type 1 patients (mean age 21.08 months, range 1–93) were available for analysis. After six months of treatment, 47 children (77.0%) improved by ≥4 points in CHOP INTEND score. Mean change in CHOP INTEND score was 9.0±8.0 points. Nineteen patients (31.1%) improved by ≥2 points in HINE-2 motor milestones. Regression analysis revealed age at onset of treatment as major determinant of change in CHOP INTEND from baseline. CONCLUSION: When analyzing a broad spectrum of SMA type 1 patients, many children showed an improvement of motor function after six months of treatment with nusinersen, which is generally not expected within the natural course of the disease. Long-term observation and follow-up of patients with later onset types of SMA are crucial to understand the clinical impact of treatment with nusinersen. |
format | Online Article Text |
id | pubmed-6004898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-60048982018-06-25 Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany Pechmann, Astrid Langer, Thorsten Schorling, David Stein, Sabine Vogt, Sibylle Schara, Ulrike Kölbel, Heike Schwartz, Oliver Hahn, Andreas Giese, Kerstin Johannsen, Jessika Denecke, Jonas Weiß, Claudia Theophil, Manuela Kirschner, Janbernd J Neuromuscul Dis Research Report BACKGROUND: Spinal muscular atrophy (SMA) is a neuromuscular disorder characterized by muscle weakness and muscle atrophy. Nusinersen acts as a splicing modifier and has recently been approved for intrathecal treatment of SMA. OBJECTIVE: Prior to approval, nusinersen was provided to patients with SMA type 1 in Germany within an Expanded Access Program (EAP). In contrast to previous clinical trials, children of different age groups and different stages of the disease were treated with nusinersen. METHODS: We conducted a prospective, longitudinal data collection of patients treated with nusinersen within the EAP in seven neuromuscular centers in Germany. Standardized assessments including CHOP-INTEND and HINE-2 motor milestones were performed at baseline and 60 and 180 days after start of treatment. RESULTS: Data from 61 SMA type 1 patients (mean age 21.08 months, range 1–93) were available for analysis. After six months of treatment, 47 children (77.0%) improved by ≥4 points in CHOP INTEND score. Mean change in CHOP INTEND score was 9.0±8.0 points. Nineteen patients (31.1%) improved by ≥2 points in HINE-2 motor milestones. Regression analysis revealed age at onset of treatment as major determinant of change in CHOP INTEND from baseline. CONCLUSION: When analyzing a broad spectrum of SMA type 1 patients, many children showed an improvement of motor function after six months of treatment with nusinersen, which is generally not expected within the natural course of the disease. Long-term observation and follow-up of patients with later onset types of SMA are crucial to understand the clinical impact of treatment with nusinersen. IOS Press 2018-05-29 /pmc/articles/PMC6004898/ /pubmed/29689734 http://dx.doi.org/10.3233/JND-180315 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Report Pechmann, Astrid Langer, Thorsten Schorling, David Stein, Sabine Vogt, Sibylle Schara, Ulrike Kölbel, Heike Schwartz, Oliver Hahn, Andreas Giese, Kerstin Johannsen, Jessika Denecke, Jonas Weiß, Claudia Theophil, Manuela Kirschner, Janbernd Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title_full | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title_fullStr | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title_full_unstemmed | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title_short | Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany |
title_sort | evaluation of children with sma type 1 under treatment with nusinersen within the expanded access program in germany |
topic | Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6004898/ https://www.ncbi.nlm.nih.gov/pubmed/29689734 http://dx.doi.org/10.3233/JND-180315 |
work_keys_str_mv | AT pechmannastrid evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT langerthorsten evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT schorlingdavid evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT steinsabine evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT vogtsibylle evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT scharaulrike evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT kolbelheike evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT schwartzoliver evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT hahnandreas evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT giesekerstin evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT johannsenjessika evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT deneckejonas evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT weißclaudia evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT theophilmanuela evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany AT kirschnerjanbernd evaluationofchildrenwithsmatype1undertreatmentwithnusinersenwithintheexpandedaccessprogramingermany |